In the news today the court battle between Lily and Amylin came to a close
the court decided against Amylin's claim of violation of collaboration laws with Lily. In this case, Amylin demanded that Lily would stop the use of its current sales force to promote Amylin's competitive drugs base on collaboration agreements between Lily and Amylin.
How PR is released and disseminated are 2 different things.The statement below is the first part of my post on the fact the lawsuit continues,but press with Amylin has always been weak.Witness a dozen or so examples from the recent News on the juvenile diabetes deal,or pancreatic,Amylin ALWAYS does it poorly,as opposed to Novo who,using the pancreatic example PR and wrote about the issue being overblown.I agree this is a ploy by those covering,but lends credence to the fact that Amylin are novices in pharma. ---------------------------------
Amylin continues to believe that Lilly's conduct violates our diabetes collaboration agreements, is anti-competitive and limits patients' treatment options. It is important to note that the Court's decision did not make any findings on the merits of our claims, but merely declines to award injunctive relief, based on the conclusion that monetary damages would be sufficient. We intend to vigorously pursue the litigation to enforce our legal and contractual rights."
The complete order is being filed on Amylin's Current Report on Form 8-K with the Securities and Exchange Commission.